LifeWatch AG

EQS-Adhoc: LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service


EQS Group-Ad-hoc: LifeWatch AG / Key word(s): Regulatory Approval
LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service

09.02.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
LifeWatch(TM) receives FDA clearance for its continuous Vital Signs Monitoring
Service

Zug/Switzerland, February 9, 2016 - LifeWatch AG (SIX Swiss Exchange: LIFE), a
leading developer and provider of medical solutions and remote diagnostic
monitoring services in the digital health market, is pleased to announce that it
has received FDA clearance for its continuous Vital Signs Monitoring Service.

The wireless, patch-based vital signs monitoring system makes vital signs
monitoring faster, easier and more convenient for both, patients and medical
staff. It will allow for early detection of vital sign changes thereby enabling
faster interventions as well as increased nursing efficiency and higher patient
satisfaction.

The Vital Signs Patch is an easy-to-use cable-free sensor worn on a patient's
upper chest. It is intended to be used on adult patients in a clinical
environment for the continuous, non-invasive monitoring of ECG, heart rate,
respiration rate, surface temperature, arterial blood oxygen saturation and body
position. It will be available in two versions (with and without ECG) and is
connected with an easy-to-use wireless supporting system, which provides medical
information and alerts remotely to medical staff. Although the system will
initially be used in a medical facility (hospital, nursing home, etc.), the even
larger ambulatory market should follow once the technology has been proven in
the clinical environment.

Dr. Stephan Rietiker, CEO of LifeWatch, stated: "This clearance represents
another significant technological breakthrough for LifeWatch and further
strengthens our position as an innovational leader in digital health. I am
highly excited at the tremendous market potential for the easy-to-use Vital
Signs Patch, both in the clinical and ambulatory settings worldwide.
Furthermore, the cost benefits will allow vital signs monitoring to be utilized
for a much broader patient population. However, providing service in a clinical
environment is a new market for LifeWatch and will therefore require both time
and additional resources in order to ensure a successful market launch."


For further questions:

LifeWatch AG
c/o Dynamics Group, Philippe Blangey / Doris Rudischhauser
Phone: +41 43 268 32 35 / +41 79 410 81 88
E-mail: investor-relations@lifewatch.com


About LifeWatch AG:
LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE),
Switzerland, is a leading healthcare technology and solution company,
specializing in advanced digital health systems and wireless remote diagnostic
patient monitoring services. LifeWatch's services provide physicians with
critical information to determine appropriate treatment and thereby improve
patient outcomes. LifeWatch AG has operative subsidiaries in the United States,
in Switzerland and in Israel, and is the parent company of LifeWatch Services
Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading
U.S.-based provider of cardiac monitoring services and home sleep testing of
Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is
a leading developer and manufacturer of telemedicine products. For additional
information, please visitwww.lifewatch.com.

Sign upfor customized e-mail alerts and documentation requests at
http://www.irlifewatch.com/alert-service.aspx

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position, the
business strategy, and plans and objectives for future operations, are
forward-looking statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar expressions are
intended to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short-term and long-term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL
CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN
OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE
UNITED STATES, OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF
LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES
SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED
STATES OR TO U.S. PERSONS ABSENT FROM REGISTRATION UNDER OR AN APPLICABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES
LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS
SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE
ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.

End of ad hoc announcement

+++++
Additional features:

Document:http://n.eqs.com/c/fncls.ssp?u=SOCCCRLJKY
Document title: LifeWatch(TM) receives FDA clearance for its continuous  Vital
Signs Monitoring Service

--------------------------------------------------------------------------------
09.02.2016 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.
--------------------------------------------------------------------------------

Language: English

Company:  LifeWatch AG

          Baarerstrasse 139

          6300  Zug

          Switzerland

Phone:    +41 41 728 67 78

Internet: www.lifewatch.com

ISIN:     CH0012815459

Valor:    811189

Listed:   Regulated Unofficial Market in Berlin, Stuttgart; Open Market in
Frankfurt ; SIX


End of News EQS Group News Service
--------------------------------------------------------------------------------
435611  09.02.2016 
 



Weitere Meldungen: LifeWatch AG

Das könnte Sie auch interessieren: